BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 22200553)

  • 1. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.
    Cao H; Huang H; Xu W; Chen D; Yu J; Li J; Li L
    Anal Chim Acta; 2011 Apr; 691(1-2):68-75. PubMed ID: 21458633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry.
    Yin P; Wan D; Zhao C; Chen J; Zhao X; Wang W; Lu X; Yang S; Gu J; Xu G
    Mol Biosyst; 2009 Aug; 5(8):868-76. PubMed ID: 19603122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.
    Lian JS; Liu W; Hao SR; Guo YZ; Huang HJ; Chen DY; Xie Q; Pan XP; Xu W; Yuan WX; Li LJ; Huang JR
    Chin Med J (Engl); 2011 May; 124(9):1367-73. PubMed ID: 21740750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
    Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
    J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations.
    Chen J; Wang W; Lv S; Yin P; Zhao X; Lu X; Zhang F; Xu G
    Anal Chim Acta; 2009 Sep; 650(1):3-9. PubMed ID: 19720165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.
    Sun C; Chen P; Chen Q; Sun L; Kang X; Qin X; Liu Y
    Acta Biochim Biophys Sin (Shanghai); 2012 Sep; 44(9):765-73. PubMed ID: 22751611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
    Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
    J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
    Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.
    Wu H; Xue R; Dong L; Liu T; Deng C; Zeng H; Shen X
    Anal Chim Acta; 2009 Aug; 648(1):98-104. PubMed ID: 19616694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
    Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
    Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma.
    El-Mir MY; Badia MD; Luengo N; Monte MJ; Marin JJ
    Clin Sci (Lond); 2001 May; 100(5):499-508. PubMed ID: 11294690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma.
    Attallah AM; El-Far M; Abdel Malak CA; Zahran F; Farid K; Omran MM; Zagloul H; El-Deen MS
    Clin Chim Acta; 2011 Nov; 412(23-24):2310-5. PubMed ID: 21924253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.